Article citationsMore>>

Mahgoub, N., Agarkar, S., Radosta, M., Fakih, F., Calleran, B., Clark, R., Cherubin, D., Faour, F. and Anthony, D. (2021) Experiences and Challenges While Managing the Inpatient Psychiatry Unit Dedicated for COVID-19 Patients. Open Journal of Psychiatry, 11, 12-19.
https://doi.org/10.4236/ojpsych.2021.111002

has been cited by the following article:

• TITLE: Life Is Quantum Biology Effects Explained from the Schrödinger Equation, Serious or Life-Threatening Conditions or Diseases, and COVID-19 Results

  AUTHORS: Huu S. Tieu, Martin F. Loeffler

  KEYWORDS: Cellular Therapy, COVID-19, Serious or Life-Threatening Conditions or Diseases, Schrödinger Equation, Blood-Brain Barrier, Immunology

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.10 No.10, October 19, 2022

  ABSTRACT: Background: A plant based approach was undertaken to ascertain the efficacy of the Technology/Innovation of a new medical Technology based on similar activity to the circulatory system of plants. Basic Technology formulations were introduced into plant structures to evaluate the responses for cell division and plant growth which ultimately lead to the final product. This Technology/Innovation transforms and enhances common botanical/herb products such that they can be used to treat COVID-19 infection and Serious or Life-threatening conditions or diseases. They can restore the diseased cell’s abnormal metabolism to homeostasis and return it to normal function by slowing or reversing the cell’s malfunctioning metabolism, or in other words, slowing or reversing the disease process. Methods: A systematic treatment for COVID-19 infection and Serious or Life-threatening illness in patients is based on theories of traditional Chinese medicine. The Technology/Innovation is developed as dietary supplement products for treatment of Serious or Life-threatening conditions or diseases. Results: The results consist of over one hundred Serious or Life-threatening patient medical records. The U.S. Food and Drug Administration (FDA) reviewed/evaluated/accepted the Technology/Innovation patient medical record results, which included fifty-four COVID-19 patients with Prioritized Review Expedited No.: 2020-2867 CR2020-2596 information on September 16, 2020 and twenty-seven cancer patients Cancer Survival Rate Results in (Table 1) with FDA Establishment Identification No.: 3012327979 information on March 25, 2019 as FDA-Regulated medical products and meet the requirement under FDA Significant Scientific Agreement standards.